Heart Failure with Preserved Ejection Fraction (HFpEF): Part 1 Review of Experience and Evidence in PARAGON-HF with Commentary

Abstract

Heart failure with preserved ejection fraction (HFpEF) also known as diastolic heart failure is a complex entity. It is due to a variety of causes and has heterogeneous presentations and, therefore, has evaded evidence that is compelling for developing standard guidelines for therapeutic intervention. In February 2021, the US Federal Drug Agency approved Sacubitril-Valsartan (angiotensin receptor neprilysin inhibitor-angiotensin receptor blocker: ARNI-ARB) combination for HFpEF. The present review outlines the current experience and management of HFpEF. It also focuses on the evidence in the PARAGON-HF trial and provides a commentary. The second part of the review shall discuss the emerging importance of SGLT2 inhibitors for HFpEF.

Keywords

• Cardiovascular clinical trials, Heart failure, HFpEF, Heart failure with preserved ejection fraction, PARAGON-HF, Sacubitril-Valsartan.